Antibody Cross-Reactivity Testing Using the HuProt™ Human Proteome Microarray
Analysis of several commercially available antibodies against 81% of the human proteome.
CONCLUSION: The use of protein microarrays to evaluate antibodies is likely to set new quality standards to evaluate antibody cross-reactivity, and will also address the need for new methods to identify antibodies that can be used in robust scientific investigations, grant proposals and for commercialization.
* Funding agencies such as the NIH have started to adopt higher standards for commercial antibodies that are to be selected for use in grant-funded research.
See the recent NIH notice NOT-OD-15-103 (Enhancing Reproducibility through Rigor and Transparency, in effect for grants submitted after January, 25 2016)
Authentication of Key Biological and/or Chemical Resources
CDI will test your antibodies against thousands of proteins - native & denatured - and at 2 working concentrations and will report back to you in detail within 2 weeks.
MAb Development Platform
CDI will produce a monospecific antibody to your target protein in 8 weeks in this fully-customizable process. Need an antigen? No problem, CDI has access to ~20,000 human proteins.
CDI offers its HuProt Human Proteome Microarray as a stand-alone product. It’s the world’s largest collection of unique, individually-purified human proteins - 16,152 gene products - on a single slide.